Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;31(4):641-649.
doi: 10.1016/j.nec.2020.06.011.

Targeting the Tumor Microenvironment in Brain Metastasis

Nisha Giridharan  1 , Isabella C Glitza Oliva  2 , Barbara J O'Brien  3 , Brittany C Parker Kerrigan  1 , Amy B Heimberger  1 , Sherise D Ferguson  4
Affiliations
Review

Targeting the Tumor Microenvironment in Brain Metastasis

Nisha Giridharan et al. Neurosurg Clin N Am. 2020 Oct.

Abstract

Dynamic interplay between cancer cells and the surrounding microenvironment is a feature of the metastatic process. Successful metastatic brain colonization requires complex mechanisms that ultimately allow tumor cells to adapt to the unique microenvironment of the central nervous system, evade immune destruction, survive, and grow. Accumulating evidence suggests that components of the brain tumor microenvironment (TME) play a vital role in the metastatic cascade. In this review, the authors summarize the contribution of the TME to the development and progression of brain metastasis. They also highlight opportunities for TME-directed targeted therapy.

Keywords: Astrocytes; Brain metastasis; Immunotherapy; Targeted therapy; Tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The authors declare no conflicts of interest. Disclosure N. Giridharan: nothing to disclose. I.C. Glitza: Research Support: BMS, Merck; Consultant: BMS, Novartis, ARRAY. B.J. O’Brien: Seattle Genetics: honorarium for educational talk; A.B. Heimberger: Advisory board: Caris Life Science, Western IRB; Stock: Caris; Licensed intellectual property/milestone payments: Celldex Therapeutics, DNAtrix; Other support: Moleculin; S.D. Ferguson: nothing to disclose.